المؤلفون: Hiruma S; Division of Diabetes, Metabolism and Endocrinology, Department of Medicine, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, Japan., Shigiyama F; Division of Diabetes, Metabolism and Endocrinology, Department of Medicine, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, Japan., Hisatake S; Division of Cardiovascular Medicine, Department of Internal Medicine, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, Japan., Mizumura S; Department of Radiology, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, Japan., Shiraga N; Department of Radiology, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, Japan., Hori M; Department of Radiology, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, Japan., Ikeda T; Division of Cardiovascular Medicine, Department of Internal Medicine, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, Japan., Hirose T; Division of Diabetes, Metabolism and Endocrinology, Department of Medicine, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, Japan., Kumashiro N; Division of Diabetes, Metabolism and Endocrinology, Department of Medicine, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, Japan. naoki.kumashiro@med.toho-u.ac.jp.

المصدر: Cardiovascular diabetology [Cardiovasc Diabetol] 2021 Feb 02; Vol. 20 (1), pp. 32. Date of Electronic Publication: 2021 Feb 02.

نوع المنشور: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE

مواضيع طبية MeSH: Adiposity/*drug effects , Benzhydryl Compounds/*therapeutic use , Cardiovascular Diseases/*prevention & control , Diabetes Mellitus, Type 2/*drug therapy , Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use , Energy Metabolism/*drug effects , Glucosides/*therapeutic use , Heart/*drug effects , Myocardium/*metabolism , Sitagliptin Phosphate/*therapeutic use , Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use, Adult ; Benzhydryl Compounds/adverse effects ; Biomarkers/blood ; Blood Glucose/drug effects ; Blood Glucose/metabolism ; Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/metabolism ; Cardiovascular Diseases/physiopathology ; Diabetes Mellitus, Type 2/diagnosis ; Diabetes Mellitus, Type 2/metabolism ; Diabetes Mellitus, Type 2/physiopathology ; Dipeptidyl-Peptidase IV Inhibitors/adverse effects ; Female ; Glucosides/adverse effects ; Glycated Hemoglobin/metabolism ; Heart/physiopathology ; Humans ; Male ; Middle Aged ; Primary Prevention ; Prospective Studies ; Sitagliptin Phosphate/adverse effects ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects ; Time Factors ; Tokyo ; Treatment Outcome